Literature DB >> 16611331

Transforming growth factor beta-induced connective tissue growth factor and chronic allograft rejection.

K Csencsits1, S C Wood, G Lu, S M Faust, D Brigstock, E J Eichwald, C G Orosz, D K Bishop.   

Abstract

Late loss of allograft function is primarily attributed to chronic rejection (CR). There are no effective treatments for CR and the underlying cause of the disease is unknown. This study compared events that occurred within cardiac allografts placed in mice that received either anti-CD4 therapy and develop CR or anti-CD40L therapy and do not develop CR. Both TGFbeta and connective tissue growth factor (CTGF), which is induced by TGFbeta, were expressed in grafts with CR but were not expressed in grafts without CR. TGFbeta transfection of allografts in anti-CD40L-treated recipients resulted in CTGF expression and CR. However, TGFbeta transfection of syngeneic grafts did not result in CTGF expression or CR. These data indicate that TGFbeta alone is insufficient to induce CR and that CTGF is required. Further, antigenic stimulation is required for TGFbeta induction of CTGF. Thus, CTGF may serve as a therapeutic target for CR.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16611331     DOI: 10.1111/j.1600-6143.2006.01292.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  14 in total

1.  Association of intronic DNA methylation and hydroxymethylation alterations in the epigenetic etiology of dilated cardiomyopathy.

Authors:  Ali M Tabish; Mohammed Arif; Taejeong Song; Zaher Elbeck; Richard C Becker; Ralph Knöll; Sakthivel Sadayappan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-04-26       Impact factor: 4.733

Review 2.  Molecular pathways involved in loss of graft function in kidney transplant recipients.

Authors:  Valeria R Mas; Kellie J Archer; Mariano Scian; Daniel G Maluf
Journal:  Expert Rev Mol Diagn       Date:  2010-04       Impact factor: 5.225

3.  Recipient-derived EDA fibronectin promotes cardiac allograft fibrosis.

Authors:  Adam J Booth; Sherri C Wood; Ashley M Cornett; Alyssa A Dreffs; Guanyi Lu; Andrés F Muro; Eric S White; D Keith Bishop
Journal:  J Pathol       Date:  2012-01-04       Impact factor: 7.996

4.  Transplant acceptance following anti-CD4 versus anti-CD40L therapy: evidence for differential maintenance of graft-reactive T cells.

Authors:  S C Wood; G Lu; B E Burrell; D K Bishop
Journal:  Am J Transplant       Date:  2008-10       Impact factor: 8.086

5.  Connective tissue growth factor promotes fibrosis downstream of TGFbeta and IL-6 in chronic cardiac allograft rejection.

Authors:  A J Booth; K Csencsits-Smith; S C Wood; G Lu; K E Lipson; D K Bishop
Journal:  Am J Transplant       Date:  2009-09-25       Impact factor: 8.086

6.  Critical role for IL-6 in hypertrophy and fibrosis in chronic cardiac allograft rejection.

Authors:  J A Diaz; A J Booth; G Lu; S C Wood; D J Pinsky; D K Bishop
Journal:  Am J Transplant       Date:  2009-06-16       Impact factor: 8.086

7.  Endogenous memory CD8 T cells are activated within cardiac allografts without mediating rejection.

Authors:  K Setoguchi; Y Hattori; S Iida; W M Baldwin; R L Fairchild
Journal:  Am J Transplant       Date:  2013-08-05       Impact factor: 8.086

Review 8.  Late kidney allograft loss: what we know about it, and what we can do about it.

Authors:  Anthony M Jevnikar; Roslyn B Mannon
Journal:  Clin J Am Soc Nephrol       Date:  2008-03       Impact factor: 8.237

9.  Role of T cell TGFbeta signaling and IL-17 in allograft acceptance and fibrosis associated with chronic rejection.

Authors:  Susan M Faust; Guanyi Lu; Bernard L Marini; Weiping Zou; David Gordon; Yoichiro Iwakura; Yasmina Laouar; D Keith Bishop
Journal:  J Immunol       Date:  2009-11-16       Impact factor: 5.422

10.  TGFbeta neutralization within cardiac allografts by decorin gene transfer attenuates chronic rejection.

Authors:  Susan M Faust; Guanyi Lu; Sherri C Wood; D Keith Bishop
Journal:  J Immunol       Date:  2009-11-16       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.